Moderna cancer vaccine reduces melanoma’s return by 44%
statnews.com
statnews.com
Here's the press release:
https://investors.modernatx.com/news/news-details/2022/Moder...
Really impressive, as the study is 44% compared with pembrolizumab, which is not bad by itself either!
Even more impressive is that it's two big companies working TOGETHER, and have an agreement to split profits!